

28



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**13.02.2002 Bulletin 2002/07**

(51) Int Cl.7: **C12N 15/12, C07K 14/78,  
C07K 16/18**

(21) Application number: **01912238.1**

(86) International application number:  
**PCT/JP01/01871**

(22) Date of filing: **09.03.2001**

(87) International publication number:  
**WO 01/66736 (13.09.2001 Gazette 2001/37)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

(30) Priority: **09.03.2000 JP 2000006595**

(71) Applicants:  
• **Japan Science and Technology Corporation**  
**Kawaguchi-shi, Saitama 332-0012 (JP)**  
• **Takahashi, Kenichi**  
**Kobe-shi, Hyogo 655-0854 (JP)**

(72) Inventors:  
• **TAKAHASHI, Kenichi**  
**Kobe-shi, Hyogo 655-0854 (JP)**  
• **TAKAI, Yoahimi**  
**Kobe-shi, Hyogo 651-2102 (JP)**  
• **NAKANISHI, Hiroyuki**  
**Kobe-shi, Hyogo 651-2103 (JP)**  
• **SATO, Kelko**  
**Nishi-ku, Kobe-shi, Hyogo 651-2112 (JP)**

(74) Representative: **Gardner, Rebecca**  
**Frank B. Dehn & Co. 179 Queen Victoria Street**  
**London EC4V 4EL (GB)**

(54) **PROTEINS NECTIN-3**

(57) This application provides a novel protein, nectin-3 having an amino acid sequence of any of SEQ ID NO: 2, 4 or 6, which belongs to a nectin protein family participating in cell-cell adhesion. It also provides a polynucleotide that codes for the nectin-3 and has a base sequence of any of SEQ ID NO: 1, 3 or 5; a recombinant vector having the polynucleotide; and an antibody against the protein nectin-3. The protein nectin-3 provides important information for clarifying all aspects of

the molecular mechanism in cell-cell binding systems, and, in addition, it leads to the possibility of clarifying the mechanism of, for example, humectation and metastasis of carcinoma, and is expected to be applicable to diagnosis of carcinoma for its malignancy and to a method for treating cases with carcinoma and also to development of medicines for carcinoma.

**EP 1 179 592 A1**

**Description****TECHNICAL FIELD**

[0001] The invention of this application relates to a novel protein nectin-3 that participates in cadherin-based cell-cell adherens junctions, and to gene-engineering materials for obtaining and utilizing the protein.

**BACKGROUND ART**

[0002] Cell-cell adhesion systems to be formed by transmembrane proteins, such as adhesion molecules, receptors and channels play an important role in various cell-level phenomena such as cell-cell adhesion, cell movement and cell morphology determination in animal individuals. Above all, cell-cell adherens junctions (AJs) bear a role indispensable for histocompatibility. Evidence is increasing to say that AJs further participate in controlling cell propagation and morphologic tissue formation, in addition to their mechanistic role as above. It has become clarified that many F-actin-binding proteins play a role as a linker to link actin cytoskeletons to adhesion molecules. However, the molecule-level understanding of AJs is insufficient, and it is not clear as to which molecules may bind actin cytoskeletons to cell membranes.

[0003] To clarify this, the inventors of this application have isolated some novel F-actin-binding proteins from rats' brains, analyzed the structure of the protein especially specific to neurocytes and abundantly existing in synapses, and named it "neurabin", for which the applicant already filed a patent application (Japanese Patent Application No. 276784/1998). Further, the inventors of this application have individually isolated 1-afadin, a novel F-actin-binding protein, and ponsin, a protein that binds with 1-afadin, for both of which the applicant filed patent applications (for 1-afadin, Japanese Patent Application No. 89572/1999; for ponsin, Japanese Patent Application No. 174687/1999). Still further, the inventors of this application have identified novel proteins, nectin-1 $\alpha$ , 1 $\beta$  and nectin-2 $\alpha$ , 2 $\delta$  that function for cadherin-based AJ formation along with afadin (J. Cell Biol., 145:539-549, 1999). They have found that these nectin-1, -2 are Ca<sup>2+</sup>-independent immunoglobulin-like adhesion molecules and act on AJ formation in one system along with afadin and ponsin (Genes Cells 4:573-581, 1999; J. Biol. Chem., 275:613-618, 2000).

[0004] Clarifying the molecular mechanism of cell-cell adhesion will make it possible to clarify, for example, the mechanism of humectation and metastasis of carcinoma, and is expected to be applicable to diagnosis of carcinoma for its malignancy and to a method for treating cases with carcinoma and also to development of medicines for carcinoma. For clarifying it, it is necessary to clarify all the details of the molecules that participate in cell-cell adhesion.

[0005] The invention of this application has been made in consideration of the current situation as above, and its one object is to provide a novel protein that participates in cell-cell adherens junctions.

[0006] Another object of the invention is to provide a gene-engineering material for producing the protein.

**DISCLOSURE OF THE INVENTION**

[0007] To solve the problems noted above, this application provides a protein nectin-3 having the amino acid sequence of any of SEQ ID NO: 2, 4 or 6.

[0008] The protein nectin-3 is derived from mice, including three splicing variants expressed by mouse genomic gene (these proteins are hereinafter referred to as nectin-3 $\alpha$ , nectin-3 $\beta$ , nectin-3 $\gamma$ ).

[0009] This application also provides a polynucleotide that encodes the protein nectin-3. The polynucleotide includes genomic DNA, mRNAs and cDNAs.

[0010] This application further provides cDNAs each encoding the three types of nectin-3, or that is, polynucleotides each having the base sequence of any of SEQ ID NO: 1, 3 or 5.

[0011] This application still further provides a recombinant vector having any of these polynucleotides.

[0012] This application still further provides an antibody against any of the three types of protein nectin-3.

[0013] Like nectin-1 and nectin-2, the protein nectin-3 of this invention is common to all mammals, existing in any and every mammal. Therefore, the protein nectin-3 and the polynucleotide encoding it are not limited to only mouse-derived ones.

**BRIEF DESCRIPTION OF THE DRAWINGS**

[0014]

Fig. 1 is to compare the amino acid sequences of nectin-3 $\alpha$ , -3 $\beta$  and -3 $\gamma$ . The black background indicates the identical sequence among the three variants; the gray background indicates the identical sequence between nectin-3 $\beta$  and -3 $\gamma$ ; the underline indicates the signal peptide; the double underlines indicate the transmembrane regions;

and the asterisks indicate the glycosylated sites in asparagina.

Fig. 2 shows the experimental data of trans homo-interaction of nectin-3 $\alpha$ . (A) indicates the expression level of nectin-3 $\alpha$ , for which a cell lysate was subjected to development in SDS-PAGE followed by Western blot analysis with a polyclonal anti-nectin-3 $\alpha$  antibody. (B) indicates cell aggregation activities of parental L cells (o) and nectin-3 $\alpha$ -expressing L cells (\*). (C) indicates cell aggregation activities of parental L cells (C1) and nectin-3 $\alpha$ -expressing L cells (C2). The bar is 100  $\mu$ m.

Fig. 3 shows the experimental data of cis homo-dimerization of nectin-3 $\alpha$ . Nectin-3 $\alpha$ -expressing cells were incubated in the presence or absence of BS3; each cell lysate was subjected to development in SDS-PAGE followed by Western blot analysis with a polyclonal anti-nectin-3 $\alpha$  antibody. The arrow indicates the monomer, and the arrowhead indicates the dimer.

Fig. 4 shows the experimental data of mixed-cell aggregation activities of labeled nectin-1 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells (A1 to A3), labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-1 $\alpha$ -expressing L cells (B1 to B3), and labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells (C1 to C3). A1, B1 and C1 are the images in interference contrast microscopy; A2, B2 and C2 are the images in fluorescence microscopy; A3, B3 and C3 are the data in statistical analysis. The bars are 40  $\mu$ m.

Fig. 5 shows the images in immunofluorescence microscopy of co-cultured two L cell lines of nectin-1 $\alpha$ -expressing L cells and -2 $\alpha$ -expressing L cells (A1 to A3), nectin-3 $\alpha$ -expressing L cells and -1 $\alpha$ -expressing L cells (B1 to B3), and nectin-3 $\alpha$ -expressing L cells and -2 $\alpha$ -expressing L cells (C1 to C3). In A1 and B2, seen is nectin-1 $\alpha$ ; in A2 and C2, nectin-2 $\alpha$ ; in B1, nectin-3 $\alpha$  (monoclonal antibody); in C1, nectin-3 $\alpha$  (polyclonal antibody); and in A3, B3 and C3, merged. The bars are 10  $\mu$ m.

Fig. 6 shows the experimental data of trans hetero-interaction affinity, for which a cell composition (labeled and unlabeled cells) of two-cell aggregates was quantitatively analyzed. A indicates the data of labeled nectin-1 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells; B indicates the data of labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-1 $\alpha$ -expressing L cells; and C indicates the data of labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells.

Fig. 7 shows the experimental data of cis hetero-dimerization nectin-3 $\alpha$  with nectin-1 $\alpha$  or -2 $\alpha$ . A is for comparison of cis dimerization. A1 indicates the data of nectin-1 $\alpha$ -expressing L cells (lane 1) and -1 $\alpha$ /3 $\alpha$ -expressing L cells (lane 2); A2 indicates the data of nectin-2 $\alpha$ -expressing L cells (lane 1) and -2 $\alpha$ /3 $\alpha$ -expressing L cells (lane 2). B shows the data of immunoprecipitation. B1 indicates the data of nectin-1 $\alpha$ /3 $\alpha$ -expressing L cells; B2 indicates the data of nectin-2 $\alpha$ /3 $\alpha$ -expressing L cells. The cell extract is in lane 1; the supernatant is in lane 2; the precipitate is in lane 3. The arrows indicate monomers; and the arrowheads indicate the dimers.

Fig. 8 shows the experimental data of nectin-3 distribution in tissues. A shows the data of Northern blot analysis of nectin-1 (A1), nectin-2 (A2) and nectin-3 (A3). B shows the data of Northern blot analysis of nectin-3 $\alpha$  (B1), nectin-3 $\beta$  (B2) and nectin-3 $\gamma$  (B3). Lane 1 is in heart; lane 2 is in brain; lane 3 is in spleen; lane 4 is in lung; lane 5 is in liver; lane 6 is in skeletal muscle; lane 7 is in kidney; and lane 8 is in testis.

Fig. 9 shows the experimental data of intracellular localization of nectin-3 $\alpha$  in mouse small intestine absorptive epithelia. In A, seen is nectin-3 $\alpha$ ; in B, nectin-2; and in C, merged. The asterisks indicate the inner space of small intestines. The bar is 10  $\mu$ m.

Fig. 10 shows the experimental data of direct binding of afadin to nectin-3 $\alpha$ . The arrow indicates a fusion protein, GST-nectin-3 $\alpha$ -CP; and the arrowhead indicates a fusion protein, MBP-afadin-PDZ.

## BEST MODE FOR CARRYING OUT THE INVENTION

[0015] A mouse protein, nectin-3 $\alpha$  is encoded by 1650 bp cDNA having the base sequence of SEQ ID NO: 1, and this has the sequence of 549 amino acids as in SEQ ID NO: 2. The complete cDNA of the nectin-3 $\alpha$  has the base sequence of 2178 bp as in SEQ ID NO: 7.

[0016] Nectin-3 $\beta$  is a protein encoded by 1533 bp cDNA having the base sequence of SEQ ID NO: 3, and this has the sequence of 510 amino acids as in SEQ ID NO: 4.

[0017] Nectin-3 $\gamma$  is a protein encoded by 1317 bp cDNA having the base sequence of SEQ ID NO: 5, and this has

the sequence of 435 amino acids as in SEQ ID NO: 6.

[0018] These proteins nectin-3 can be obtained in any known method, for example, according to a method of isolating them from mouse and other mammal tissues; according to a method that comprises preparing peptides through chemical synthesis based on the amino acid sequences provided by this invention; or according to a method of recombinant DNA technology using the polynucleotides provided by this invention. Concretely, nectin-3 may be obtained through recombinant DNA technology as follows: An RNA is prepared through in-vitro transcription from a vector having a polynucleotide that encodes nectin-3, and the nectin-3 is expressed in vitro through in-vitro translation using the RNA as a template. In the case of the polynucleotide encoding the nectin-3 being recombined with a suitable expression vector in a known manner, the nectin-3 encoded by the polynucleotide can be abundantly expressed in *E. coli*, *B. subtilis*, yeast, animal or plant cells, etc.

[0019] The protein nectin-3 of this invention can be expressed in microorganisms such as *E. coli*, in the following manner: The polynucleotide of this invention that encodes the protein is inserted into an expression vector having an origin replicable in microorganisms, a promoter, a ribosome-binding site, a DNA cloning site and a terminator to construct a recombinant expression vector; then host cells are transformed with the expression vector; and the resulting transformant cells are cultured. In that manner, the nectin-3 encoded by the polynucleotide can be abundantly produced in microorganisms. Alternatively, it may be expressed in the form of a fusion protein with any other protein segment. The resulting fusion protein is cleaved with a suitable protease, and only the protein segment encoded by the polynucleotide can be obtained.

[0020] The protein nectin-3 of this invention can be expressed in animal cells in the following manner: The polynucleotide of this invention that encodes the protein is recombined with an expression vector for animal cells having a promoter, a splicing region and a poly(A)-addition site, and the recombinant vector is introduced into animal cells, whereby the protein nectin-3 of this invention can be expressed in the thus-transformed animal cells.

[0021] The mouse protein nectin-3 obtained according to the method as above can be used, for example, as an antigen to form an antibody that specifically recognizes this protein.

[0022] The protein nectin-3 includes peptide fragments (of at least 5 amino acid residues) having any partial amino acid sequence of the amino acid sequence of SEQ ID NO: 2, 4 or 6. These peptide fragments are also usable as an antigen for constructing the antibody.

[0023] The polynucleotide of this invention is a genomic gene of mammals that encodes any of the above-mentioned protein nectin-3 $\alpha$ ,  $\beta$  or  $\gamma$ . For example, it can be isolated from known genomic libraries, using the polynucleotide having the base sequence of any of SEQ ID NO: 1, 3 or 5 or its partial sequence as a probe.

[0024] A polynucleotide of this invention may be cDNA characterized by having the base sequence of SEQ ID NO: 1, 3 or 5, and it encodes any of the above-mentioned nectin-3 $\alpha$ ,  $\beta$  or  $\gamma$ . Clones of the polynucleotides of this invention can be obtained with ease. Concretely, using an oligonucleotide probe synthesized on the basis of the base sequence of SEQ ID NO: 1, 3 or 5, mouse and other mammal cDNA libraries are screened. Alternatively, using the oligonucleotides as primers, the intended polynucleotides can be synthesized through polymerase chain reaction (PCR).

[0025] In general, mammal genes include many polymorphisms owing to individual differences. Therefore, polynucleotides modified from those having a base sequence of any of SEQ ID NO: 1, 3 or 5 by adding, deleting and/or substituting one or more nucleotides therein with any other nucleotide(s) are all within the scope of this invention. Similarly, proteins modified through the polynucleotide modification to add, delete and/or substitute one or more amino acid residues with any other amino acid residue(s) are also all within the scope of this invention, so far as they have the activity of the protein having the amino acid sequence of any of SEQ ID NO: 2, 4 or 6.

[0026] The polynucleotide of this invention includes DNA fragments (of at least 10 bp) having any partial base sequence of the base sequence of SEQ ID NO: 1, 3 or 5, and also polynucleotides comprising their antisense chains.

[0027] The antibody of this invention can be obtained as a polyclonal antibody or a monoclonal antibody in any known method of using the protein nectin-3 itself or its partial peptide as an antigen.

[0028] The following Examples are to show the experimental data to confirm the structure and the function of the nectin-3 of this invention.

## EXAMPLES

### 1. Procedures

#### 1.1 Molecular Cloning of Mouse Nectin-3 cDNAs

[0029] From the EST database, three different types of mouse EST clones (A11428160, AA492633, AA497887), which are similar to but are not the same as nectin-1 and -2, were amplified from a mouse brain cDNA (Clontech). Using the mixture of these cDNAs as a probe, a mouse cDNA library (Stratagene) was screened to obtain a full-length cDNA. For its DNA sequencing, used was a DNA sequencer (ABI 373).

## 1.2 Construction of Nectin-3 Expression Vectors

[0030] Vectors pCAGIPuro (J. Biol. Chem., 275: 613-618, 2000), pCAGIPuro-FLAG, p-GEX-KG (Anal. Biochem., 192: 262-267, 1991), pMal-C2 (New England Biolabs Inc.) and pFastBac1-Msp-Fc (J. Cell Biol., 145: 539-549, 1999) were used for constructing nectin-3 expression vectors mentioned below. The pCAGIPuro-FLAG was constructed by subcloning a prepro-trypsin signal peptide and the FLAG epitope of p FLAG-CMV1 (Eastman Kodak) into pCAGIPuro.

- (a) pCAGIPuro-nectin-3 $\alpha$ : 1-549 amino acids (full length) of SEQ ID NO: 2,
- (b) pCAGIPuro-FLAG-nectin-3 $\alpha$ : 56-549 amino acids of SEQ ID NO: 2,
- (c) GST-nectin-3 $\alpha$ -CP: 433-549 amino acids of SEQ ID NO: 2 (cytoplasmic region),
- (d) GST-nectin-3 $\alpha$ -CP- $\Delta$ C: 433-545 amino acids of SEQ ID NO: 2 (deletion of the C-terminal four amino acid residues),
- (e) GST-nectin-3 $\gamma$ -CP: 397-438 amino acids of SEQ ID NO: 6 (cytoplasmic region),
- (f) pFastBac1-Msp-Fc-nectin-3 $\alpha$ -EX: 56-400 amino acids of SEQ ID NO: 2 (extracellular region)

## 1.3 Construction of Transformant Cells

[0031] L cells (obtained from the Kyoto University) were cultured in a 10% fetal calf serum-containing DMEM medium to prepare parental L cells for transformation. Full-length human nectin-1 $\alpha$ -expressing L cells (nectin-1 $\alpha$ -L cells) and full-length mouse nectin-2 $\alpha$ -expressing L cells (nectin-2 $\alpha$ -L cells) were constructed according to the method described in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Full-length mouse nectin-3 $\alpha$ -expressing L cells (nectin-3 $\alpha$ -L cells) were constructed, using a recombinant vector pCAGIPuro-nectin-3 $\alpha$ . Nectin-1 $\alpha$  and FLAG-nectin-3 $\alpha$ -coexpressing L cells (nectin-1 $\alpha$ /3 $\alpha$ -L cells), and nectin-2 $\alpha$  and FLAG-nectin-3 $\alpha$ -coexpressing L cells (nectin-2 $\alpha$ /3 $\alpha$ -L cells) were constructed by transfecting the nectin-1 $\alpha$ -L cells and the nectin-2 $\alpha$ -L cells, respectively, with pCAGIPuro-FLAG-nectin-3 $\alpha$ , using a lipofectamine reagent (GIBCO BRL). Each cell line was cultured for 1 day, replated, and selected by culturing in the presence of 5  $\mu$ g/ml of puromycin (Sigma Chemical Co.).

## 1.4 Preparation of Antibodies:

[0032] A rabbit antiserum (polyclonal antibody) against nectin-3 $\alpha$  was raised against an antigen, GST-nectin-3 $\alpha$ -CP. A rat monoclonal antibody against nectin-3 was raised against an antigen, fusion protein of the extracellular region of nectin-3 $\alpha$  with IgG Fc. A rabbit polyclonal anti-nectin-1 $\alpha$  antibody was prepared according to the method described in a reference (J. Cell Biol., 145: 539-549, 1999). Another rabbit polyclonal anti-nectin-1 $\alpha$  antibody was raised against an antigen, synthetic peptide corresponding to the amino acid sequence 450-468 of nectin-1 $\alpha$ , according to the method described in the reference (J. Cell Biol., 145: 539-549, 1999). A rat monoclonal anti-nectin-2 antibody was prepared according to the method described in references (J. Cell Biol., 145: 539-549, 1999; Exp. Cell Res., 235: 374-384, 1997); and mouse monoclonal and rabbit polyclonal anti-1-afadin antibodies were prepared according to the method described in references (J. Cell Biol., 139: 517-528, 1997; Oncogene 18: 1609-1618, 1999). A rat monoclonal anti-E-cadherin antibody was obtained from Dr. Takeichi (Kyoto University). A mouse monoclonal anti-FLAG antibody was bought from Eastman Kodak.

## 1.5 Other Procedures

[0033] Cell aggregation assay was done according to the method described in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). For mixed-cell aggregation assay between two different L cell lines, one L cell line was prelabeled with Dil (Molecular Probes Inc., USA), as described (J. Cell Biol., 103: 171-187, 1986).

[0034] Chemical cross-linking was done according to the method described in references (Blood 92: 4602-4611, 1998; J. Biol. Chem., 275: 613-618, 2000). Immunoprecipitation was performed according to the method described in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Immunofluorescence microscopy of cultured cells was done according to the method described in references (J. Cell Biol., 139: 517-528, J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Protein concentrations were determined with bovine serum albumin as a control, according to the method described in a reference (Anal. Biochem., 72: 248-254, 1976). SDS-PAGE was done as described (Nature, 227: 680-685, 1970).

[0035] Affinity chromatography was performed as follows: The MBP-fusion protein of the PDZ domain of afadin was immobilized on amylose resin beads (New England Biolabs Inc.). GST-nectin-3 $\alpha$ -CP and GST-nectin-3 $\alpha$ -CP- $\Delta$ C were separately applied to the affinity beads. After extensively washed with PBS (containing 0.1 % Triton X-100), the beads were subjected to elution with PBS (containing 20 mM maltosa, 0.1 % Triton X-100).

## 2. Results

## 2.1 Cloning and Characterization of Nectin-3 cDNAs

**[0036]** The cDNA clone obtained from the mouse cDNA library has the base sequence of SEQ ID NO: 7, and encoded a protein (calculated molecular weight: 60,580) comprising 549 amino acids (SEQ ID NO: 2) in the 1647 bp coding region (SEQ ID NO: 1). This clone contained all the above-mentioned EST clones. The protein was named nectin-3 $\alpha$ . **[0037]** The amino acid sequence of The nectin-3 $\alpha$  had an N-terminal hydrophobic signal peptide (1-55 amino acids of SEQ ID NO: 2) and a transmembrane region (405-421 amino acids of SEQ ID NO: 2). The sites for N-linked glycosylation were detected at 73, 83, 125, 186, 222 and 331 amino acids. The nectin-3 contained three Ig-like domains in the extracellular region and a C-terminal conserved motif in the cytoplasmic region (Table 1).

Table 1

C-Terminal Sequences of the Nectin Family	
Members	
Nectin-1 $\alpha$	SFISKKEWYV
Nectin-1 $\beta$	VRTTEPRGEC
Nectin-2 $\alpha$	SLISRRVYV
Nectin-2 $\delta$	DEFVSRAMYV
Nectin-3 $\alpha$	SVISRREWYV
Nectin-3 $\beta$	LYINPREHYV
Nectin-3 $\gamma$	LGQVRALEDT

**[0038]** As in the above, these structural properties of nectin-3 $\alpha$  are similar to those of nectin-1 $\alpha$ , -1 $\beta$ , -2 $\alpha$  and -2 $\delta$ . The extent of homology varied with the regions of the molecules, but the amino acid sequence of the extracellular region of nectin-3 $\alpha$  showed 35.9 % and 30.7 % identities to those of nectin-1 and nectin-2, respectively.

**[0039]** During the isolation of nectin-3 $\alpha$ , two splicing variants (nectin-3 $\beta$  and -3 $\gamma$ ) were isolated. The nectin-3 $\beta$  cDNA (coding region) has a base sequence of 1533 bps (SEQ ID NO: 3), and encodes a protein having an amino acid sequence of 510 amino acids (SEQ ID NO: 4, calculated molecular weight: 55,808). The extracellular region of nectin-3 $\beta$  (1-357 amino acids of SEQ ID NO: 4) is identical to that of nectin-3 $\alpha$ , but its transmembrane and cytoplasmic regions (358-510 amino acids of SEQ ID NO: 4) are different from those of nectin-3 $\alpha$ . However, nectin-3 $\beta$  also has a C-terminal conserved motif (Table 1).

**[0040]** The nectin-3 $\gamma$  cDNA (coding region) has a base sequence of 1317 bps (SEQ ID NO: 5), and encodes a protein having an amino acid sequence of 438 amino acids (SEQ ID NO: 6, calculated molecular weight: 47,259). The extracellular region, transmembrane region and cytoplasmic region of nectin-3 $\gamma$  are identical to those of nectin-3 $\beta$ , but nectin-3 $\gamma$  lacks the C-terminal conserved motif (Table 1).

**[0041]** Fig. 1 is to compare the amino acid sequences (in one-letter coding) of these nectin-3 $\alpha$ , -3 $\beta$  and -3 $\gamma$ .

**[0042]** The following experiments are principally directed to nectin-3 $\alpha$ . This is because the data in Northern blot analysis of various tissues confirm that nectin-3 $\alpha$  is a major splicing variant (see Fig. 8, B1 to B3).

## 2.2 trans Homo-interaction and cis Homo-dimer Formation

**[0043]** Studies with nectin-1 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells confirm that nectin-1 $\alpha$  and nectin-2 $\alpha$  show cell-cell adhesion activity (trans homo-interaction) (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). With that, here in examined was whether nectin-3 $\alpha$  also shows the same activity. The polyclonal anti-nectin-3 $\alpha$  antibody recognized two protein bands with molecular masses of about 100 kDa in the expression products by nectin-3 $\alpha$ -L cells (Fig. 2A, Fig. 3). This may be due to the different levels of the post-translational modification such as glycosylation. These molecular masses are different from the calculated molecular weight based on the deduced amino acid sequence. This difference may also be due to the glycosylation. The expression level of nectin-1 $\alpha$ , -2 $\alpha$  and -3 $\alpha$  in each cell line was almost the same (data not shown).

**[0044]** Nectin-3 $\alpha$ -L cells were tested for the cell aggregation activity of nectin-3 $\alpha$ . As a result, the cell aggregation activity of nectin-3 $\alpha$  varied time-dependently (Fig. 2B, C1, C2). EDTA added to nectin-3 $\alpha$  did not have any influence on this activity of nectin-3 $\alpha$  (data not shown). This confirms that the cell-cell adhesion activity of nectin-3 $\alpha$  does not depend on Ca<sup>2+</sup>. These results indicate that nectin-3 $\alpha$  is a Ca<sup>2+</sup>-independent homophilic CAM (cell adhesion molecule),

like nectin-1 $\alpha$ , -2 $\alpha$  and -2 $\delta$  (J. Cell Biol., 145: 539-549, 1999; Exp. Cell Res., 235: 374-384, 1997; Blood, 92: 4602-4611, 1998; J. Biol. Chem., 275: 613-618, 2000).

[0045] Nectin-1 $\alpha$  and -2 $\alpha$  are known to show cis homo-dimerization (J. Biol. Chem., 275: 613-618, 2000). With that, nectin-3 $\alpha$  was also tested for the same activity. Nectin-3 $\alpha$ -L cells were dissociated to a single-cell suspension and incubated with a cell surface cross-linker, BS3, and then subjected to Western blot analysis using a polyclonal anti-nectin-3 $\alpha$  antibody. The cross-linking of the cell line resulted in the formation of additional bands with molecular masses of about 200 to 220 kDa that correspond to dimers (Fig. 3). Bands with higher molecular masses were also detected. Because the cross-linking was done in a single-cell suspension, it is most likely that the dimers and oligomers are derived from the cis homo-interaction rather than from the trans homo-interaction.

### 2.3 trans Hetero-Interaction of Nectin-3 $\alpha$ with Nectin-1 $\alpha$ or -2 $\alpha$

[0046] To examine whether each member of the nectin family shows heterophilic cell-cell adhesion activity (trans hetero-interaction), mixed-cell aggregation assay was performed. When Dil-labeled nectin-1 $\alpha$ -L cells were mixed with unlabeled nectin-2 $\alpha$ -L cells, the resulting aggregates exclusively consisted of the labeled cells alone or the unlabeled cells alone (Fig. 4 A1-A3). Few aggregates consisting of both the labeled and unlabeled cells were detected. In contrast, when Dil-labeled nectin-3 $\alpha$ -L cells were mixed with unlabeled nectin-1 $\alpha$ -L cells, the resulting aggregates consisted of both the labeled cells and the unlabeled cells (Fig. 4, B1-B3). This indicates that nectin-3 $\alpha$  shows trans hetero-interaction with nectin-1 $\alpha$ . The similar result was obtained with nectin-3 $\alpha$  and nectin-2 $\alpha$  (Fig. 4, C1-C3).

[0047] To confirm these results, immunofluorescence microscopy was performed. When nectin-1 $\alpha$ -L cells were co-cultured with nectin-2 $\alpha$ -L cells, nectin-1 $\alpha$  and nectin-2 $\alpha$  were localized in the cell-cell contact sites of the respective L cells (Fig. 5, A1-A3). However, neither nectin-1 $\alpha$  nor nectin-2 $\alpha$  was detected in the contact sites of the two types of the L cells. In contrast, when nectin-3 $\alpha$ -L cells were co-cultured with nectin-1 $\alpha$ -L cells, nectin-3 $\alpha$  and nectin-1 $\alpha$  coexisted in the cell-cell contact site of the two types of the L cells (Fig. 5, B1-B3). The same result was obtained in co-culture of nectin-3 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells (Fig. 5, C1-C3). These results indicate that nectin-3 $\alpha$  shows trans hetero-interaction with nectin-1 $\alpha$  and -2 $\alpha$ , whereas nectin-1 $\alpha$  does not trans hetero-interaction with nectin-2 $\alpha$ .

[0048] To determine whether each member of the nectin family prefers trans homo-interaction or trans hetero-interaction, two-cell aggregates were analyzed through mixed-cell aggregation assay. Consistent with the result in the analysis of two-cell aggregates, the mixture of nectin-1 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells resulted in the formation of homotypic two-cell aggregates (Fig. 6A). In contrast, the mixture of nectin-1 $\alpha$ -L cells and nectin-3 $\alpha$ -L cells resulted in the formation of heterotypic two-cell aggregates, and few homotypic two-cell aggregates were found (Fig. 6B). The similar result was obtained when nectin-3 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells were mixed (Fig. 6C). These results indicate that the affinity of trans hetero-interaction of nectin-3 $\alpha$  with nectin-1 $\alpha$  or -2 $\alpha$  is obviously higher than that of trans homo-interaction of nectin-1 $\alpha$ , -2 $\alpha$  or -3 $\alpha$ .

### 2.4 cis Hetero-dimerization of Nectin-3 $\alpha$ with Nectin-1 $\alpha$ or -2 $\alpha$

[0049] Next examined was whether nectin-3 $\alpha$  forms a cis hetero-dimer with nectin-1 $\alpha$  or -2 $\alpha$ . Using nectin-1 $\alpha$ /3 $\alpha$ -L cells and nectin-2 $\alpha$ /3 $\alpha$ -L cells, FLAG-nectin-3 $\alpha$  was expressed in the nectin-1 $\alpha$ -L cells and the nectin-2 $\alpha$ -L cells. As a result, the FLAG-nectin-3 $\alpha$  expressed did not change the size of the cis dimers of nectin-1 $\alpha$  or -2 $\alpha$  (Fig. 7, A1 and A2). When nectin-1 $\alpha$ /3 $\alpha$ -L cells were subjected to cell surface cross-linking, followed by immunoprecipitation using the monoclonal anti-FLAG antibody, then nectin-1 $\alpha$  was recovered in the supernatant and was not coimmunoprecipitated with FLAG-nectin-3 $\alpha$  (Fig. 7, B1). The similar result was obtained with nectin-2 $\alpha$ /3 $\alpha$ -L cells (Fig. 7, B2). These results indicate that nectin-3 $\alpha$  does not form a cis hetero-dimer with nectin-1 $\alpha$  or -2 $\alpha$ .

### 2.5 Tissue Distribution and Intracellular Localization of Nectin-3 $\alpha$

[0050] Consistent with previous reports (J. Virol., 66: 2807-2813, 1992; Gene 155: 261-265, 1995; Gene 159: 267-272, 1995), Northern blot analysis revealed that nectin-1 is abundantly expressed in brain whereas nectin-2 is ubiquitously expressed (Fig. 8, A1 and A2). Northern blot analysis using, as a probe, the coding region common to the three splicing variants of nectin-3 revealed some mRNA bands in various tissues (Fig. 8, A3). To determine the tissue distribution of each splicing variant, a cDNA probe specific to each variant was used. Nectin-3 $\alpha$  gave about 5.2-kb, 3.8-kb, 3.3-kb and 2.7-kb mRNA bands, abundantly expressed in testis but slightly in other tissues (heart, brain, lung, liver and kidney) (Fig. 8, B1). Nectin-3 $\beta$  gave about 5.2-kb and 3.3-kb mRNA bands, expressed in testis (Fig. 8, B2). Nectin-3 $\gamma$  gave an about 3.3-kb mRNA band in testis, and an about 2.1-kb mRNA band in lung, liver and kidney (Fig. 8, B3).

[0051] To determine the intracellular localization of nectin-3 $\alpha$ , immunofluorescence microscopy was performed, using a polyclonal anti-nectin-3 $\alpha$  antibody. Nectin-3 $\alpha$  was colocalized with nectin-2 in the junctional complex regions in mouse

small intestine absorptive epithelia (Fig. 9). These results suggest that nectin-3 $\alpha$  is also localized at cadherin-based cell-cell AJs, like nectin-2 (J. Cell Biol., 145: 539-549, 1999).

## 2.6 Direct Binding of Nectin-3 to Afadin

[0052] To confirm whether nectin-3 $\alpha$  directly binds to afadin, affinity chromatography was performed. The GST-fusion protein in the cytoplasmic region of nectin-3 $\alpha$  (GST-nectin-3 $\alpha$ -CP) bound to the MBP-fusion protein in the PDZ domain of afadin (MBP-afadin-PDZ) immobilized on amylose resin beads (Fig. 10). The stoichiometry of binding of nectin-3 $\alpha$  to afadin was about 1:1. In contrast, the GST-fusion protein in the C-terminal four amino acid residues-deleted cytoplasmic region of nectin-3 $\alpha$  (GST-nectin-3 $\alpha$ -CP- $\Delta$ C) did not bind to the affinity beads. Similarly, the GST-fusion protein in the cytoplasmic region of nectin-3 $\gamma$  that lacks the C-terminal conserved motif did not also bind to the affinity beads.

## INDUSTRIAL APPLICABILITY

[0053] As described in detail hereinabove, the invention of this application provides a novel protein nectin-3 that belongs to one and the same protein family to which nectin-1 and -2 belong. The protein provides important information for clarifying all aspects of the molecular mechanism in cell-cell binding systems, and, in addition, it leads to the possibility of clarifying the mechanism of, for example, humectation and metastasis of carcinoma, and is expected to be applicable to diagnosis of carcinoma for its malignancy and to a method for treating cases with carcinoma and also to development of medicines for carcinoma.



SEQUENCE LISTING

5 <110> Japan Science and Technology Corporation

<120> Protein Nectine-3

10 <130> 00-F-039PCT/YS

<140> PCT/JP01/01871

15 <141> 2001-03-09

<150> JP 2000-65595

20 <151> 2000-03-09

<160> 7

25 <170> PatentIn Ver. 2.1

<210> 1

<211> 1650

<212> DNA

35 <213> Mouse

<220>

40 <221> CDS

<222> (1).. (1650)

<300>

45 <301> Satoh-Horikawa K. et al.

<302> Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows  
homophilic and heterophilic cell-cell adhesion activities.

50 <303> J. Biol. Chem.

<304> 275

55 <305> 14

&lt;306&gt; 10291-10299

&lt;307&gt; 2000-04-07

5

&lt;400&gt; 1

10

atg gcg cgg acc ccg ggc ccg gcc ccg ttg tgt cct gga ggc ggc aaa 48

Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys

1 5 10 15

15

gca caa ctt tcc tgc gcg ttt cct ccc gcg gcc gga ctg ctg ctg ccg 96

Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro

20 25 30

20

gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att ccc ctg ctt ctc 144

Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu

25

35 40 45

30

ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att att gtg gag cca 192

Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro

50 55 60

35

cat gtc aca gca gtg tgg gga aag aat gtt tca ttg aag tgt tta att 240

His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile

65 70 75 80

40

gaa gtg aat gaa act ata acc cag atc tca tgg gag aag ata cat ggc 288

Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly

45

85 90 95

50

aaa agt aca cag act gtt gca gtt cat cat cct cag tat gga ttc tct 336

Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser

100 105 110

55

gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt 384

Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125

aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga 432

Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140

aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc 480

Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 145 150 155 160

tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa 528

Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 165 170 175

ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt 576

Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190

tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt 624

Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 195 200 205

gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca 672

Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 210 215 220

gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga 720

Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
 225 230 235 240

gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac 768

Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp

	245	250	255	
5	att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca			816
	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser			
10	260	265	270	
	gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac			864
	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn			
15	275	280	285	
	ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg			912
20	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp			
	290	295	300	
25	agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat			960
	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn			
	305	310	315	320
30	act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat			1008
	Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr			
35	325	330	335	
	gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt gat caa aag gtt			1056
40	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val			
	340	345	350	
45	atc tac att tca gat cct cct acc acc acc acc ctt cag ccg aca gtt			1104
	Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu Gln Pro Thr Val			
	355	360	365	
50	cag tgg cat tcc tca cct gct gac gtc cag gat ata gca aca gag cat			1152
	Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile Ala Thr Glu His			
	370	375	380	

5      aaa aaa ttg ccc ttt cct ttg tca act ttg gca aca ctt aag gat gac 1200  
       Lys Lys Leu Pro Phe Pro Leu Ser Thr Leu Ala Thr Leu Lys Asp Asp  
       385                      390                      395                      400

10      aca att ggc acc atc att gct agt gta gtg ggt ggg gct ctc ttc tta 1248  
       Thr Ile Gly Thr Ile Ile Ala Ser Val Val Gly Gly Ala Leu Phe Leu  
                                  405                      410                      415

15      gtg ctt gtg agc att tta gct ggg gta ttc tgc tat agg aga cga cgg 1296  
       Val Leu Val Ser Ile Leu Ala Gly Val Phe Cys Tyr Arg Arg Arg Arg  
                                  420                      425                      430

20      acg ttt cgt gga gac tac ttt gcc aaa aac tac att cca cca tca gac 1344  
       Thr Phe Arg Gly Asp Tyr Phe Ala Lys Asn Tyr Ile Pro Pro Ser Asp  
                                  435                      440                      445

25      atg cag aaa gaa tca cag att gat gtt ctt cac cag gat gag ctg gat 1392  
       Met Gln Lys Glu Ser Gln Ile Asp Val Leu His Gln Asp Glu Leu Asp  
                                  450                      455                      460

30      tct tac cca gac agt gta aaa aag gaa aac aaa aat cca gta aac aac 1440  
       Ser Tyr Pro Asp Ser Val Lys Lys Glu Asn Lys Asn Pro Val Asn Asn  
       465                      470                      475                      480

35      ctg atc cgc aaa gac tac tta gag gag cct gag aaa act cag tgg aat 1488  
       Leu Ile Arg Lys Asp Tyr Leu Glu Glu Pro Glu Lys Thr Gln Trp Asn  
                                  485                      490                      495

40      aat gta gag aac ctc act agg ttt gaa aga ccg atg gat tac tat gaa 1536  
       Asn Val Glu Asn Leu Thr Arg Phe Glu Arg Pro Met Asp Tyr Tyr Glu  
                                  500                      505                      510

gat cta aaa atg gga atg aag ttt gtc agt gat gaa cgc tac aat gaa 1584  
 Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu Arg Tyr Asn Glu  
 5 515 520 525

agt gaa gat ggt ttg gtt tct cat gta gat ggc tcc gta att tcc agg 1632  
 Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser Val Ile Ser Arg  
 10 530 535 540

agg gag tgg tat gtc taa 1650  
 Arg Glu Trp Tyr Val  
 15 545 550

<210> 2  
 <211> 549  
 <212> PRT  
 <213> Mouse  
 20

<400> 2  
 Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
 35 1 5 10 15  
 Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
 20 25 30  
 Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile Pro Leu Leu Leu  
 40 35 40 45  
 Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro  
 45 50 55 60  
 His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile  
 65 70 75 80  
 Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly  
 50 85 90 95  
 Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
 55 100 105 110

Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125  
 5 Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140  
 Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 10 145 150 155 160  
 Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 165 170 175  
 15 Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190  
 Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 20 195 200 205  
 Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 210 215 220  
 25 Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
 225 230 235 240  
 Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp  
 30 245 250 255  
 Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser  
 260 265 270  
 35 Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn  
 275 280 285  
 Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp  
 290 295 300  
 40 Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn  
 305 310 315 320  
 Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr  
 45 325 330 335  
 Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val  
 340 345 350  
 50 Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu Gln Pro Thr Val  
 355 360 365  
 55 Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile Ala Thr Glu His

370                      375                      380  
 Lys Lys Leu Pro Phe Pro Leu Ser Thr Leu Ala Thr Leu Lys Asp Asp  
 5    385                      390                      395                      400  
 Thr Ile Gly Thr Ile Ile Ala Ser Val Val Gly Gly Ala Leu Phe Leu  
                                  405                      410                      415  
 10 Val Leu Val Ser Ile Leu Ala Gly Val Phe Cys Tyr Arg Arg Arg Arg  
                                  420                      425                      430  
 Thr Phe Arg Gly Asp Tyr Phe Ala Lys Asn Tyr Ile Pro Pro Ser Asp  
 15                      435                      440                      445  
 Met Gln Lys Glu Ser Gln Ile Asp Val Leu His Gln Asp Glu Leu Asp  
                                  450                      455                      460  
 20 Ser Tyr Pro Asp Ser Val Lys Lys Glu Asn Lys Asn Pro Val Asn Asn  
 465                      470                      475                      480  
 Leu Ile Arg Lys Asp Tyr Leu Glu Glu Pro Glu Lys Thr Gln Trp Asn  
 25                      485                      490                      495  
 Asn Val Glu Asn Leu Thr Arg Phe Glu Arg Pro Met Asp Tyr Tyr Glu  
                                  500                      505                      510  
 30 Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu Arg Tyr Asn Glu  
                                  515                      520                      525  
 Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser Val Ile Ser Arg  
 35                      530                      535                      540  
 Arg Glu Trp Tyr Val  
 545

45 <210> 3  
 <211> 1533  
 <212> DNA  
 <213> Mouse

50 <220>  
 55 <221> CDS



&lt;222&gt; (1).. (1533)

&lt;300&gt;

&lt;301&gt; Satoh-Horikawa K. et al.

&lt;302&gt; Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities.

&lt;303&gt; J. Biol. Chem.

&lt;304&gt; 275

&lt;305&gt; 14

&lt;306&gt; 10291-10299

&lt;307&gt; 2000-04-07

&lt;308&gt; GenBank accession No. AF195834

&lt;309&gt; 2000-04-13

&lt;400&gt; 3

atg gcg ccg acc ccg ggc ccg gcc ccg ttg tgt cct gga ggc ggc aaa 48

Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys

1 5 10 15

gca caa ctt tcc tcg gcg ttt cct ccc gcg gcc gga ctg ctg ctg ccg 96

Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro

20 25 30

gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att ccc ctg ctt ctc 144

Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu

35 40 45

ttc tcc ccg ctc tgt ggt gcc tta gct gga tca att att gtg gag cca 192

Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro

50 55 60

cat gtc aca gca gtg tgg gga aag aat gtt tca ttg aag tgt tta att 240

His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile

EP 1 179 592 A1

	65	70	75	80	
5	gaa gtg aat gaa act ata acc cag atc tca tgg gag aag ata cat ggc				288
	Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly				
10		85	90	95	
	aaa agt aca cag act gtt gca gtt cat cat cct cag tat gga ttc tct				336
15	Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser				
	100	105	110		
20	gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt				384
	Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu				
	115	120	125		
25	aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga				432
	Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly				
	130	135	140		
30	aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc				480
	Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser				
35	145	150	155	160	
	tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa				528
40	Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys				
	165	170	175		
45	ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt				576
	Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val				
	180	185	190		
50	tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt				624
	Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly				
	195	200	205		
55					

5      gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca    672  
       Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
           210                    215                    220

10      gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga    720  
       Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
       225                    230                    235                    240

15      gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac    768  
       Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp  
 20                    245                    250                    255

25      att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca    816  
       Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser  
           260                    265                    270

30      gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac    864  
       Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn  
           275                    280                    285

35      ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg    912  
       Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp  
 40            290                    295                    300

45      agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat    960  
       Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn  
       305                    310                    315                    320

50      act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat    1008  
       Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr  
           325                    330                    335

55

EP 1 179 592 A1

5	gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt gat caa aag gtt	1056
	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val	
	340 345 350	
10	atc tac att tca gac atc ccg ctt acg cag acc tca tcc ata gca gtg	1104
	Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val	
	355 360 365	
15	gct gga gcc gtg att gga gct gtc ctg gcc ctc ttc atc atc acc gtc	1152
	Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val	
20	370 375 380	
25	ttt gtg act gtg ttg ctg acg cct cgg aaa aag aga ccg tcc tat ctt	1200
	Phe Val Thr Val Leu Leu Thr Pro Arg Lys Lys Arg Pro Ser Tyr Leu	
	385 390 395 400	
30	gac aaa gta atc gac ctt cca cct aca cat aag cca ccc cct gta tat	1248
	Asp Lys Val Ile Asp Leu Pro Pro Thr His Lys Pro Pro Pro Val Tyr	
	405 410 415	
35	gaa gaa cga att cct tct ctc cct cag aaa gac ctt ctt ggc cag act	1296
	Glu Glu Arg Ile Pro Ser Leu Pro Gln Lys Asp Leu Leu Gly Gln Thr	
	420 425 430	
40	gaa cac ttg cct ttg cag act cag ttc aag gag aaa gga gct ggt ggt	1344
	Glu His Leu Pro Leu Gln Thr Gln Phe Lys Glu Lys Gly Ala Gly Gly	
45	435 440 445	
50	ctt cag ccc tct aat gga cca att agc agg aga ttt gac tat gag gat	1392
	Leu Gln Pro Ser Asn Gly Pro Ile Ser Arg Arg Phe Asp Tyr Glu Asp	
	450 455 460	
55	gag agc aca atg caa gaa gat gga act cag cgc atg tgc ccc ctt tat	1440

5      Glu Ser Thr Met Gln Glu Asp Gly Thr Gln Arg Met Cys Pro Leu Tyr  
       465                      470                      475                      480

10      agc cag atg tgc cac caa gac cga agc cct cgc caa cat cac cca cgc      1488  
       Ser Gln Met Cys His Gln Asp Arg Ser Pro Arg Gln His His Pro Arg  
                                  485                      490                      495

15      aac ccc gag aga ctc tac atc aac cca cga gaa cat tat gtg tga      1533  
       Asn Pro Glu Arg Leu Tyr Ile Asn Pro Arg Glu His Tyr Val  
                                  500                      505                      510

20      <210> 4  
       <211> 510  
       <212> PRT  
       <213> Mouse

30      <400> 4  
       Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
           1                      5                      10                      15

35      Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
                                  20                      25                      30

40      Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile Pro Leu Leu Leu  
                                  35                      40                      45

      Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro  
           50                      55                      60

45      His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile  
           65                      70                      75                      80

      Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly  
                                  85                      90                      95

50      Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
                                  100                      105                      110

55      Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu

	115	120	125
5	Asn Asp Ala Thr Ile Thr	Leu His Asn Ile Gly Phe	Ser Asp Ser Gly
	130	135	140
	Lys Tyr Ile Cys Lys Ala Val	Thr Phe Pro Leu Gly Asn Ala Gln Ser	
10	145	150	155
	Ser Thr Thr Val Thr Val	Leu Val Glu Pro Thr Val Ser Leu Ile Lys	
	165	170	175
	Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val		
15	180	185	190
	Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly		
	195	200	205
20	Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr		
	210	215	220
	Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg		
25	225	230	235
	Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp		
	245	250	255
30	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser		
	260	265	270
	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn		
35	275	280	285
	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp		
	290	295	300
40	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn		
	305	310	315
	Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr		
	325	330	335
45	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val		
	340	345	350
	Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val		
50	355	360	365
	Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val		
	370	375	380

5 Phe Val Thr Val Leu Leu Thr Pro Arg Lys Lys Arg Pro Ser Tyr Leu  
 385 390 395 400  
 Asp Lys Val Ile Asp Leu Pro Pro Thr His Lys Pro Pro Pro Val Tyr  
 405 410 415  
 10 Glu Glu Arg Ile Pro Ser Leu Pro Gln Lys Asp Leu Leu Gly Gln Thr  
 420 425 430  
 Glu His Leu Pro Leu Gln Thr Gln Phe Lys Glu Lys Gly Ala Gly Gly  
 435 440 445  
 15 Leu Gln Pro Ser Asn Gly Pro Ile Ser Arg Arg Phe Asp Tyr Glu Asp  
 450 455 460  
 Glu Ser Thr Met Gln Glu Asp Gly Thr Gln Arg Met Cys Pro Leu Tyr  
 20 465 470 475 480  
 Ser Gln Met Cys His Gln Asp Arg Ser Pro Arg Gln His His Pro Arg  
 485 490 495  
 25 Asn Pro Glu Arg Leu Tyr Ile Asn Pro Arg Glu His Tyr Val  
 500 505 510

30  
 <210> 5

35 <211> 1317

<212> DNA

<213> Mouse

40 <220>

<221> CDS

45 <222> (1).. (1317)

<300>

<301> Satoh-Horikawa K. et al.

50 <302> Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows  
 homophilic and heterophilic cell-cell adhesion activities.

<303> J. Biol. Chem.

55

&lt;304&gt; 275

&lt;305&gt; 14

&lt;306&gt; 10291-10299

&lt;307&gt; 2000-04-07

&lt;308&gt; GenBank accession No. AF195835

&lt;309&gt; 2000-04-13

&lt;400&gt; 5

atg gcg cgg acc ccg gcc ccg ccg ttg tgt cct gga gcc gcc aaa 48

Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys

1 5 10 15

gca caa ctt tcc tcg gcg ttt cct ccc gcg gcc gga ctg ctg ctg ccg 96

Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro

20 25 30

gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att ccc ctg ctt ctc 144

Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu

35 40 45

ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att att gtg gag cca 192

Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro

50 55 60

cat gtc aca gca gtg tgg gga aag aat gtt tca ttg aag tgt tta att 240

His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile

65 70 75 80

gaa gtg aat gaa act ata acc cag atc tca tgg gag aag ata cat gcc 288

Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly

85 90 95

aaa agt aca cag act gtt gca gtt cat cat cct cag tat gga ttc tct 336



Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
 100 105 110

5

gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt 384  
 Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125

10

aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga 432  
 Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140

15

aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc 480  
 Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 145 150 155 160

20

tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa 528  
 Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 165 170 175

30

ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt 576  
 Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190

35

tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt 624  
 Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 195 200 205

40

gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca 672  
 Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 210 215 220

45

gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga 720  
 Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg

50

55

	225	230	235	240	
5					
	gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac				768
	Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp				
10		245	250	255	
	att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca				816
15		Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser			
		260	265	270	
	gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac				864
20		Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn			
		275	280	285	
25	ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg				912
	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp				
		290	295	300	
30	agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat				960
	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn				
35		305	310	315	320
	act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat				1008
40		Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr			
		325	330	335	
	gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt gat caa aag gtt				1056
45		Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val			
		340	345	350	
50	atc tac att tca gac atc ccg ctt acg cag acc tca tcc ata gca gtg				1104
	Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val				
		355	360	365	

55

5 gct gga gcc gtg att gga gct gtc ctg gcc ctc ttc atc atc acc gtc 1152  
 Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val  
 370 375 380

10 ttt gtg act gtg ttg ctg acg cct cgg aaa aag aga ccg tcc tat ctt 1200  
 Phe Val Thr Val Leu Leu Thr Pro Arg Lys Lys Arg Pro Ser Tyr Leu  
 385 390 395 400

15 gac aaa gta atc gac ctt cca cct aca cat aag cca ccc cct gta tat 1248  
 Asp Lys Val Ile Asp Leu Pro Pro Thr His Lys Pro Pro Pro Val Tyr  
 405 410 415

20 gaa gaa cga att cct tct ctc cct cag aaa gac ctt ctt ggc cag gta 1296  
 Glu Glu Arg Ile Pro Ser Leu Pro Gln Lys Asp Leu Leu Gly Gln Val  
 420 425 430

30 cgt gct ctc gaa gac act taa 1317  
 Arg Ala Leu Glu Asp Thr  
 435

35

40 <210> 6  
 <211> 438  
 <212> PRT  
 <213> Mouse

45 <400> 6  
 Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
 1 5 10 15

50 Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
 20 25 30  
 Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile Pro Leu Leu Leu

55

EP 1 179 592 A1

	35	40	45
5	Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro		
	50	55	60
	His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile		
	65	70	75
10	Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly		
	85	90	95
	Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser		
15	100	105	110
	Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu		
	115	120	125
20	Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly		
	130	135	140
	Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser		
25	145	150	155
	Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys		
	165	170	175
30	Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val		
	180	185	190
	Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly		
35	195	200	205
	Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr		
	210	215	220
40	Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg		
	225	230	235
	Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp		
	245	250	255
45	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser		
	260	265	270
	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn		
50	275	280	285
	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp		
	290	295	300

55

5 Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn  
 305 310 315 320  
 Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr  
 325 330 335  
 10 Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val  
 340 345 350  
 Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val  
 15 355 360 365  
 Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val  
 370 375 380  
 20 Phe Val Thr Val Leu Leu Thr Pro Arg Lys Lys Arg Pro Ser Tyr Leu  
 385 390 395 400  
 Asp Lys Val Ile Asp Leu Pro Pro Thr His Lys Pro Pro Pro Val Tyr  
 405 410 415  
 25 Glu Glu Arg Ile Pro Ser Leu Pro Gln Lys Asp Leu Leu Gly Gln Val  
 420 425 430  
 Arg Ala Leu Glu Asp Thr  
 30 435

35

&lt;210&gt; 7

&lt;211&gt; 2178

40

&lt;212&gt; DNA

&lt;213&gt; Mouse

45

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (197).. (1846)

50

&lt;300&gt;

&lt;301&gt; Satoh-Horikawa K. et al.

&lt;302&gt; Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows

55

homophilic and heterophilic cell-cell adhesion activities.

<303> J. Biol. Chem.

<304> 275

<305> 14

<306> 10291-10299

<307> 2000-04-07

<308> GenBank accession No. AF195833

<309> 2000-04-13

<400> 7

gaattcggca cgagcgacgg cggagtcgag gcagccgca gcgtcgcc gagtggcggc 60

ggcggcgac gscgcaagag ccgggggttg aggacacgg cgctggcct tccgcgcgc 120

ggccggccc gccgcccga cccagagcct gaggcggcg gscggggcg agcgggtgg 180

ccggggcaag gggggc atg gcg cgg acc cgg ggc ccg gcc cgg ttg tgt cct 232

Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro

1

5

10

gga ggc ggc aaa gca caa ctt tcc tgg ggg ttt cct ccc ggc gcc gga 280

Gly Gly Gly Lys Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly

15

20

25

ctg ctg ctg ccg gcc ccg acg ccg ccg ctg ctg ctg ctt att 328

Leu Leu Leu Pro Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile

30

35

40

ccc ctg ctt ctc ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att 376

Pro Leu Leu Leu Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile

45

50

55

60

att gtg gag cca cat gtc aca gca gtg tgg gga aag aat gtt tca ttg 424

Ile Val Glu Pro His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu  
 5 65 70 75  
 aag tgt tta att gaa gtg aat gaa act ata acc cag atc tca tgg gag 472  
 10 Lys Cys Leu Ile Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu  
 80 85 90  
 aag ata cat ggc aaa agt aca cag act gtt gca gtt cat cat cct cag 520  
 15 Lys Ile His Gly Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln  
 95 100 105  
 tat gga ttc tct gtt caa gga gat tat cag gga aga gtc ttg ttt aaa 568  
 20 Tyr Gly Phe Ser Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys  
 110 115 120  
 aac tat tca ctt aat gat gca aca att act ctg cat aac ata ggc ttc 616  
 25 Asn Tyr Ser Leu Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe  
 125 130 135 140  
 tca gat tct gga aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga 664  
 35 Ser Asp Ser Gly Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly  
 145 150 155  
 aat gct cag tcc tct aca aca gtg act gtg tta gtt gaa ccc aca gtg 712  
 40 Asn Ala Gln Ser Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val  
 160 165 170  
 agc ctg ata aaa ggg ccg gat tct tta att gat gga ggg aat gag aca 760  
 45 Ser Leu Ile Lys Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr  
 175 180 185  
 gta gca gcc gtt tgt gta gca gcc act gga aag cca gtc gca cag att 808  
 50 Val Ala Ala Val Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile  
 55

	190	195	200	
5	gac tgg gaa ggt gat ctt ggt gaa atg gaa tct agt aca act tct ttt			856
	Asp Trp Glu Gly Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe			
	205	210	215	220
10				
	cct aat gaa aca gca acg att gtc agc caa tac aag ctg ttt ccc aca			904
	Pro Asn Glu Thr Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr			
15		225	230	235
	aga ttt gct cga gga agg cga att act tgt gtt gta aaa cat cca gcc			952
20	Arg Phe Ala Arg Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala			
	240	245	250	
25	tta gaa aag gac att cgc tac tct ttc ata cta gac ata cag tat gct			1000
	Leu Glu Lys Asp Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala			
	255	260	265	
30				
	cct gaa gtt tca gta aca gga tat gat gga aat tgg ttc gtg gga aga			1048
	Pro Glu Val Ser Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg			
35	270	275	280	
	aaa ggt gtt aac ctc aag tgt aat gct gat gca aac cct cca ccc ttc			1096
40	Lys Gly Val Asn Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe			
	285	290	295	300
	aag tcc gtg tgg agc agg ttg gat gga caa tgg cct gat ggt tta ttg			1144
45	Lys Ser Val Trp Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu			
	305	310	315	
50	gcg tca gat aat act ctt cat ttt gtc cat cca ttg act gtc aat tat			1192
	Ala Ser Asp Asn Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr			
55	320	325	330	



5 tct ggc gtt tat gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt 1240  
 Ser Gly Val Tyr Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser  
 335 340 345

10 gat caa aag gtt atc tac att tca gat cct cct acc acc acc acc ctt 1288  
 Asp Gln Lys Val Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu  
 350 355 360

15 cag ccg aca gtt cag tgg cat tcc tca cct gct gac gtc cag gat ata 1336  
 Gln Pro Thr Val Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile  
 20 365 370 375 380

25 gca aca gag cat aaa aaa ttg ccc ttt cct ttg tca act ttg gca aca 1384  
 Ala Thr Glu His Lys Lys Leu Pro Phe Pro Leu Ser Thr Leu Ala Thr  
 385 390 395

30 ctt aag gat gac aca att ggc acc atc att gct agt gta gtg ggt ggg 1432  
 Leu Lys Asp Asp Thr Ile Gly Thr Ile Ile Ala Ser Val Val Gly Gly  
 400 405 410

35 gct ctc ttc tta gtg ctt gtg agc att tta gct ggg gta ttc tgc tat 1480  
 Ala Leu Phe Leu Val Leu Val Ser Ile Leu Ala Gly Val Phe Cys Tyr  
 415 420 425

40 agg aga cga cgg acg ttt cgt gga gac tac ttt gcc aaa aac tac att 1528  
 Arg Arg Arg Arg Thr Phe Arg Gly Asp Tyr Phe Ala Lys Asn Tyr Ile  
 45 430 435 440

50 cca cca tca gac atg cag aaa gaa tca cag att gat gtt ctt cac cag 1576  
 Pro Pro Ser Asp Met Gln Lys Glu Ser Gln Ile Asp Val Leu His Gln  
 445 450 455 460

EP 1 179 592 A1

5 gat gag ctg gat tct tac cca gac agt gta aaa aag gaa aac aaa aat 1624  
 Asp Glu Leu Asp Ser Tyr Pro Asp Ser Val Lys Lys Glu Asn Lys Asn  
 465 470 475

10 cca gta aac aac ctg atc cgc aaa gac tac tta gag gag cct gag aaa 1672  
 Pro Val Asn Asn Leu Ile Arg Lys Asp Tyr Leu Glu Glu Pro Glu Lys  
 480 485 490

15 act cag tgg aat aat gta gag aac ctc act agg ttt gaa aga ccg atg 1720  
 Thr Gln Trp Asn Asn Val Glu Asn Leu Thr Arg Phe Glu Arg Pro Met  
 495 500 505

20 gat tac tat gaa gat cta aaa atg gga atg aag ttt gtc agt gat gaa 1768  
 Asp Tyr Tyr Glu Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu  
 25 510 515 520

30 cgc tac aat gaa agt gaa gat ggt ttg gtt tct cat gta gat ggc tcc 1816  
 Arg Tyr Asn Glu Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser  
 525 530 535 540

35 gta att tcc agg agg gag tgg tat gtc taa cagccactga cgcgacttca 1866  
 Val Ile Ser Arg Arg Glu Trp Tyr Val  
 545 550

40 ctatgtacaa ggtttcattc acactagtig accattttca gattgttcat actttttctt 1926

45 gaggaagaat aagctttttc aagttagatt cgagcttact ttttatattc tgatctgaca 1986

50 aatgaaaatg taaaacctgg gtccaatgta tctgagctgc ttacagttt tcactgctat 2046

55 actactgtct caagatttaa attctaagtc agagtacitt attggtctga ggcacacagg 2106

taagaaagat gtcaacgtta aatgtatgac gtttttgta caaaaattaa aaaaaaaaaa 2166

aaaaaactcg ag

2178

5

## Claims

- 10 1. A protein nectin-3 having the amino acid sequence of SEQ ID NO: 2.
2. A protein nectin-3 having the amino acid sequence of SEQ ID NO: 4.
- 15 3. A protein nectin-3 having the amino acid sequence of SEQ ID NO: 6.
4. A polynucleotide encoding the protein nectin-3 of any of claims 1 to 3.
5. The polynucleotide as claimed in claim 2, which has the base sequence of SEQ ID NO: 1.
- 20 6. The polynucleotide as claimed in claim 2, which has the base sequence of SEQ ID NO: 3.
7. The polynucleotide as claimed in claim 2, which has the base sequence of SEQ ID NO: 5.
8. A recombinant vector having the polynucleotide of any of claims 4 to 7.
- 25 9. An antibody against the protein nectin-3 of any of claims 1 to 3.

30

35

40

45

50

55

Fig.3




Fig. 4




Fig.5




Fig.6




Fig.7






Fig. 8




Fig.9





Fig.10



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01871

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.<sup>7</sup> C12N 15/12, C07K 14/78, C07K 16/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.<sup>7</sup> C12N 15/12, C07K 14/78, C07K 16/18

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

SwissProt/PIR/GeneSeq, MEDLINE (STN), Genbank/EMBL/DDBJ/GeneSeq

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Takahashi K. et al. "an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein" J Cell Biol (1999), Vol. 145, No. 3, p. 539-49	1-9
A	Miyahara M. et al. "Interaction of nectin with sfadin is necessary for its clustering at cell-cell contact sites but not for its cis dimerization or trans interaction" J Biol Chem (2000), Vol. 275, No. 1, p. 613-8	1-9
A	Asakura T et al. "Similar and differential behaviour between the nectin-afadin-ponsin and cadherin-catenin systems during the formation and disruption of the polarized junctional alignment in epithelial cells" Genes Cells (1999), Vol. 4, NO. 10, p. 573-81	1-9

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search  
27 April, 2001 (27.04.01)Date of mailing of the international search report  
15 May, 2001 (15.05.01)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.



Creation date: 11-07-2003

Indexing Officer: MCARTER5 - MARK CARTER

Team: OIPEBackFileIndexing

Dossier: 09972268

Legal Date: 28-03-2002

No.	Doccode	Number of pages
1	FOR	64
2	NPL	10
3	NPL	10
4	NPL	12
5	NPL	10
6	NPL	8
7	NPL	8
8	NPL	12
9	NPL	38
10	NPL	10
11	NPL	6
12	NPL	10
13	NPL	6
14	NPL	12
15	NPL	8
16	NPL	6
17	NPL	6
18	NPL	12
19	NPL	2
20	NPL	2
21	NPL	2
22	NPL	2
23	NPL	2
24	NPL	2
25	NPL	2
26	NPL	2

Total number of pages: 264

Remarks:

Order of re-scan issued on .....

